Alzheimer's disease is a challenging and devastating diagnosis that affects memory and cognitive skills, with no known way to predict, track, treat, or cure it effectively. In 2024, around 90 million people over the age of 65 will be living with Alzheimer's. Clinical trials for new treatments have faced high failure rates, partly because it's difficult to identify the right patients at the right stage of the disease. The potential solution to this dilemma might lie in AI, which could help analyze vast amounts of clinical data and provide a practical prognostic tool.

Our host Nick Kenny, Chief Scientific Officer at Syneos Health, is joined by Dr. Claudine Brisard, Senior Vice President of Neurosciences at Syneos Health and Dr. Christian Dansereau, CEO of Perceiv AI, to explore how AI and prognostic models might solve the challenges of selecting the right patients for Alzheimer's clinical trials.

Check out these insights for more from our experts on Alzheimer’s Disease or the use of AI to accelerate clinical trials:

BLOG: Artificial Intelligence and Alzheimer’s: Transforming Patient Screening with Predictive Models

Syneos Health Podcast | Turbo-Charging Clinical Trials

Webinar | How AI is Supercharging Clinical Trials

Artificial Intelligence, Machine Learning and a New Epoch for Clinical Trials

The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.

If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health.

Like what you’re hearing? Be sure to rate and review us!

We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.